Taylor's Initiation, page-23

Yes.

Peers post Ph 2b success:
- PAR - Ph 2b success awaiting Ph 3 trial approval $711.5m MC;
- OPT - Ph 2b success awaiting Ph 3 trial approval $809.9m MC.

Undervalued bios have typically run in the lead up to the phase 2 results. E.g. Paradigm released their Phase 2b data on the 18th of December 2018, the closing share price before the announcement was $1.29. 3-month prior $0.946-month $0.67; and12 month $0.24. BTW 0.24 was $47.7m MC - just to highlight how undervalued we are here. It ran to $200m prior to release.

As for OPT, that was $200m prior to results also - end markets of OPT and PAR are not dissimilar.

Stating the obvious here but,Dimerix currently sits 6 months before not one, but two phase two readouts right now. Should see a rerate over next few months given we are at 19.5m EV (could be up to 10x higher based on peer analysis) and a massive rerate upon success. Crazy risking when you think diabetic subset of ph2a achieved 35% and this trial just needs 30% improvement.

8's.